Recursion Pharmaceuticals (RXRX) Accumulated Expenses (2020 - 2026)

Recursion Pharmaceuticals has reported Accumulated Expenses for 7 years, with the latest figure at $54.2 million in Q1 2026.

• For the quarter ending Q1 2026, Accumulated Expenses fell 4.58% year-over-year to $54.2 million; the trailing twelve-month figure through Mar 2026 stood at $54.2 million (down 4.58% YoY), and the FY2025 full-year result was $70.2 million, down 14.22% from the prior year.
• Accumulated Expenses for Q1 2026 stood at $54.2 million, down from $70.2 million in the prior quarter.
• The five-year high for Accumulated Expenses was $81.9 million in Q4 2024, with the low at $23.1 million in Q1 2022.
• Historically, Accumulated Expenses has averaged $43.1 million across 5 years, with a median of $39.8 million in 2023.
• The largest YoY upside for Accumulated Expenses was 117.89% in 2025 against a maximum downside of 14.22% in 2025.
• Recursion Pharmaceuticals' Accumulated Expenses stood at $32.9 million in 2022, then surged by 41.73% to $46.6 million in 2023, then soared by 75.56% to $81.9 million in 2024, then dropped by 14.22% to $70.2 million in 2025, then retreated by 22.82% to $54.2 million in 2026.
• The last three Accumulated Expenses figures came in at $54.2 million (Q1 2026), $70.2 million (Q4 2025), and $53.1 million (Q3 2025), per Business Quant data.